SCHEMBL4476107

SCHEMBL4476107

CN1CCN(Cc2ccc(-c3ccccc3C(F)(F)F)cc2)CC1c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.66
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 2/20 0.44
ATM Q13315 2/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 1/20 0.40
S1PR1 P21453 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TACR1 P25103 1/20 0.40
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
HSD11B1 P28845 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489036 0.87 CNR2 (0.64) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4468418 0.87 CNR2 (0.64) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4481096 0.84 CNR2 (0.60) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4483088 0.84 CNR2 (0.60) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4465986 0.84 CNR2 (0.61) CNR2ALDH1A1KMT2AL3MBTL1
SCHEMBL4465011 0.83 CNR2 (0.59) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4465004 0.83 CNR2 (0.59) CNR2ALDH1A1KDM4EATMKMT2A
SCHEMBL4471731 0.83 CNR2 (0.58) CNR2KDM4EATMKMT2AMEN1
SCHEMBL4479887 0.83 CNR2 (0.58) CNR2KDM4EATMKMT2AMEN1
SCHEMBL4474625 0.82 CNR2 (0.66) CNR2ALDH1A1KDM4EATMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
EP-1966132-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-10 EP disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885ALDH1A1 2612/4885KDM4E 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.